Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Agilent Technologies, Inc. (A) Halal?

PASS

Agilent Technologies, Inc. · NYSE: A · Healthcare

The short answer

Yes — Agilent Technologies (A) passes this Shariah stock screen. The Santa Clara lab-instruments and diagnostics company (chromatography, mass spectrometry, pathology/genomics, CrossLab lab services; acquired Biocare Medical for $950M in June 2026) has no prohibited business lines. Total interest-bearing debt of $3,949 million ($304M short-term + $3,645M long-term at July 31, 2026) is about 7.97% of its ~$49.57 billion market cap — well under the ~33% ceiling. Interest income of $43 million is about 0.78% of nine-month revenue ($5,511M) — far under the 5% limit. Zoya, Musaffa and ShariaPortfolio all cover A and all three rate it compliant.

Gate 1 — Business activity: PASS

Agilent Technologies, Inc. (NYSE: A), spun out of Hewlett-Packard in 1999 and headquartered in Santa Clara, California, is a global provider of analytical instruments, software, services and consumables for laboratories. Its three reportable segments are Life Sciences and Diagnostics Markets (liquid/gas chromatography, mass spectrometry, atomic spectroscopy, pathology and genomics — including PD-L1 pharmDx assays), Agilent CrossLab (instrument services, lab operations and informatics) and Applied Markets (instruments for environmental, food, forensics, chemical and advanced-materials testing). In June 2026 it completed the $950 million acquisition of Biocare Medical, expanding its pathology offering. None of the disclosed lines — laboratory instruments, lab services, diagnostics/genomics — are prohibited lines (no alcohol, gambling, pork, conventional banking/insurance, tobacco, cannabis, or adult entertainment). Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

At July 31, 2026 Agilent reported short-term debt of $304M and long-term debt of $3,645M, for total interest-bearing debt of $3,949M (per the Q3 FY2026 10-Q; long-term debt rose after the issuance of $600M of 2032 senior notes, partly funding the Biocare acquisition). Against a market cap of about $49.57B (Finnhub quote, October 2026), debt ÷ market cap is about 7.97%, well below the ~33% ceiling. Cash and cash equivalents of $1,758M are about 3.55% of market cap, within the ~33% guideline. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Interest income was $43M for the nine months ended July 31, 2026 ($15M in Q3 alone), per the Q3 FY2026 income statement, against net revenue of $5,511M — about 0.78% of revenue (Q3 alone ≈ 0.80%), far below the 5% non-compliant income limit. For reference, the FY2025 10-K reported $62M of interest income on $6,948M of revenue (≈0.89%). The interest is earned on cash and investment balances, not from lending. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does Agilent Technologies do?

Agilent Technologies (NYSE: A), spun out of Hewlett-Packard in 1999 and based in Santa Clara, California, is a global provider of analytical laboratory instruments, software, services and consumables. Its three segments are Life Sciences and Diagnostics Markets (chromatography, mass spectrometry, atomic spectroscopy, pathology and genomics products such as PD-L1 pharmDx assays), Agilent CrossLab (instrument services, lab management and informatics) and Applied Markets (instruments for environmental, food, forensics, chemical and advanced-materials testing). In June 2026 it completed the $950 million acquisition of Biocare Medical to expand its pathology offering. None of the disclosed business lines are prohibited lines — no alcohol, gambling, pork, conventional banking or insurance, tobacco, cannabis or adult entertainment.

Why does Agilent Technologies pass this Shariah stock screen?

Agilent Technologies passes this Shariah stock screen on all three gates. Its business has no prohibited segments — analytical instruments, lab services and diagnostics only. Total interest-bearing debt of $3,949 million (short-term $304M + long-term $3,645M at July 31, 2026) against a market capitalization of about $49.57 billion is about 7.97%, well below the ~33% debt ceiling. Interest income of $43 million is about 0.78% of nine-month revenue of $5,511 million, far below the 5% non-compliant income ceiling. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.

What is Agilent Technologies' interest-bearing debt ratio?

At July 31, 2026 Agilent reported short-term debt of $304 million and long-term debt of $3,645 million, for total interest-bearing debt of $3,949 million (per the Q3 FY2026 10-Q balance sheet). Long-term debt rose during the quarter after Agilent issued $600 million of 2032 senior notes, partly funding the Biocare acquisition. With a market capitalization of about $49.57 billion (Finnhub, October 2026), debt divided by market cap is about 7.97%, comfortably below the ~33% ceiling. Cash and cash equivalents of $1,758 million are about 3.55% of market cap, within the ~33% guideline. Gate 2 passes.

What is Agilent Technologies' non-compliant income ratio?

For the nine months ended July 31, 2026, Agilent reported interest income of $43 million against net revenue of $5,511 million — about 0.78% of revenue, far below the 5% non-compliant income limit (Q3 alone: $15 million ÷ $1,878 million ≈ 0.80%). For reference, the FY2025 10-K reported interest income of $62 million on revenue of $6,948 million, about 0.89%. The interest is earned on cash and investment balances, not from lending. Gate 3 passes.

Do Zoya, Musaffa, or ShariaPortfolio cover Agilent Technologies?

All three cover it, and all three rate it compliant. Zoya's page for A states that as of October 2026 it is Shariah-compliant (halal), citing the FY2025 annual report ($6,948M revenue, $62M interest income ≈ 0.89%). Musaffa's page classifies Agilent as halal under its AAOIFI methodology as of October 2026. The ShariaPortfolio screener states Agilent Technologies Inc is Shariah Compliant and passes 5 of 5 of its Shariah standards. This page independently applies the screen from the company's filings: Q3 FY2026 10-Q (quarter ended July 31, 2026) and the FY2025 10-K.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).